|
|
Topics |
Replies |
Views |
Last Post |
|
|
EMEA Revised Q and A document
by GCP HelpDesk on 2009-09-01 21:57:52 |
0 |
2456 |
by GCP HelpDesk
on 2009-09-01 21:57:52
|
|
|
Interpretation of " Relevant Correspondence " in ICH GCP 8.3.11
by GCP HelpDesk on 2009-07-13 20:26:24 |
0 |
2907 |
by GCP HelpDesk
on 2009-09-01 21:47:23
|
|
|
FAQs on US-FDA IRB registration
by GCP HelpDesk on 2009-08-07 02:14:03 |
0 |
2441 |
by GCP HelpDesk
on 2009-09-01 21:47:09
|
|
|
US-FDA Guidance for Industry: Drug Induced Liver Injury: Premarketing Clinical Evaluation
by GCP HelpDesk on 2009-08-10 22:59:53 |
0 |
2059 |
by GCP HelpDesk
on 2009-09-01 21:46:52
|
|
|
Final Rules for Expanded Access to Investigational Drugs for Treatment Use
by Rajashekharam on 2009-08-14 19:17:08 |
0 |
2154 |
by Rajashekharam
on 2009-08-14 19:17:08
|
|
|
Prcoedural Advice and FAQs on PIPs
by Harrison on 2009-07-24 17:53:09 |
0 |
2422 |
by Harrison
on 2009-07-24 17:53:09
|
|
|
FDA Draft Guidance on Post-Marketing CTs
by Leon on 2009-07-24 17:46:42 |
0 |
2301 |
by Leon
on 2009-07-24 17:46:42
|